Preoperative Cisplatin and Bevacizumab in ER-, PR-, HER2 Negative Breast Cancer

Inclusion Criteria: * All tumors must be ER-, PR- and HER2-negative * Clinical stage T2 or T3, N0-3, M0. Subjects with inflammatory breast cancer are not eligible * For subjects with clinically negative axilla, a sentinel lymph node biopsy will be performed either up front or after preoperative therapy at the discretion of the subject's physicians; for subjects with a clinically positive axilla, a needle aspiration or core biopsy will be performed to confirm the presence of metastatic disease in the lymph nodes. * 18 years of age or older * Performance status (PS) of 0 or 1 * Use of an effective means of contraception in subjects of child-bearing potential * Normal organ function as described in the protocol Exclusion Criteria: * Any prior cytotoxic chemotherapy or radiation for the current breast cancer * HER2-negative ipsilateral breast recurrence, unless prior treatment consisted of excision alone for ductal carcinoma in situ (DCIS)or breast-conserving treatment and hormonal therapy for DCIS or invasive cancer * Life expectancy of less than 12 weeks * Current, recent, or planned participation in an experimental durg study other than a Genentech-sponsored bevacizumab cancer study * Renal dysfunction for which exposure to cisplatin would require dose modifications * Steroid dependent asthma * Peripheral neuropathy of any etiology that exceeds grade 1 * Uncontrolled diabetes * History of malignancy treated without curative intent * Any other pre-existing medical condition that would represent toxicity in excess of grade 1 * Inadequately controlled hypertension * Any prior history of hypertensive crisis or hypertensive encephalopathy * New York Heart Association (NYHA) Grade II or greater congestive hear failure * History of myocardial infarction or unstable angina within 12 months prior to study enrollment * Any history of stroke or transient ischemic attack at any time * Known central nervous system (CNS) disease * Significant vascular disease * Symptomatic peripheral vascular disease * Evidence of bleeding diathesis or coagulopathy * Major surgical procedure, open biopsy, or significant traumatic injury within 21 days prior to study enrollment * History of abdominal fistula, gastrointestinal perforation or intra-abdominal abscess within 6 months prior to study enrollment * Serious, non-healing wound, ulcer or bone fracture * Proteinuria at screening * Known hypersensitivity to any component of bevacizumab * Pregnant or lactating